Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1272403

registered interest
date	17/12/2020
answering body	Department for Environment, Food and Rural Affairs
answering dept id	13
answering dept short name	Environment, Food and Rural Affairs
answering dept sort name	Environment, Food and Rural Affairs
hansard heading	Coronavirus: Waste
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what evidence they have for the prevalence of COVID-19 in waste matter globally.
tabling member printed	Lord Campbell-Savours
uin	HL11572
answer	answer is ministerial correction date of answer 05/01/2021 answer text <p>International evidence on the prevalence of SARS-CoV-2 virus in human faeces, urine and wastewater has been examined by the Transmission of Covid-19 in the Wider Environment Group (TWEG), an expert group commissioned by Defra.</p><p> </p><p>This group published its initial findings in a report to SAGE on 12 June, on <a href="http://www.gov.uk" target="_blank">www.gov.uk</a>, - TWEG: Evidence of wider environmental transmission of SARS-CoV-2 - and is continuing to examine new evidence as it emerges.</p><p> </p><p>While the virus is present in human waste, evidence shows that it is rapidly inactivated so transmission risk from exposure to contaminated wastewater is assessed to be very low.</p> answering member printed Lord Goldsmith of Richmond Park question first answered 05/01/2021 15:38:19 answering member 4062 label Biography information for Lord Goldsmith of Richmond Park
tabling member	499 label Biography information for Lord Campbell-Savours

1272404

registered interest
date	17/12/2020
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Coronavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what research they have commissioned on the development of a COVID-19 vaccine which can be administered in a single dose.
tabling member printed	Lord Campbell-Savours
uin	HL11573
answer	answer is ministerial correction date of answer 04/01/2021 answer text <p>The Government has invested in a portfolio of COVID-19 vaccines across a range of modalities to secure UK access to the most promising candidates.</p><p> </p><p>The clinical trials of these vaccines involve testing their safety and efficacy across a range of scenarios, including testing efficacy rates of both single and multi-dose delivery methods.</p><p> </p><p>This will ensure the UK has early access to those vaccines that offer the most protection against COVID-19.</p> answering member printed Lord Callanan question first answered 04/01/2021 16:32:49 answering member 4336 label Biography information for Lord Callanan
tabling member	499 label Biography information for Lord Campbell-Savours

1259917

registered interest
date	09/12/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government how effective (1) an adenovirus vector, and (2) an mRNA, COVID-19 vaccine is if a person only receives one of the two doses required under the vaccination protocols.
tabling member printed	Lord Campbell-Savours
uin	HL11277
answer	answer is ministerial correction date of answer 01/02/2021 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) has recommended that as many people on the JCVI’s priority list as possible should be offered a first vaccine dose as the initial priority. One dose of the vaccine offers important protection and allows us to reach as many at risk people as possible in order to offer protection until the second dose can be administered. All individuals will subsequently receive a second dose in due course.</p><p> </p><p>It can be assumed that protection from the first dose will require boosting in order to provide more durable protection. The JCVI supports a two-dose vaccine schedule for the Pfizer-BioNTech and AstraZeneca vaccines.</p> answering member printed Lord Bethell question first answered 01/02/2021 12:33:01 answering member 4708 label Biography information for Lord Bethell
tabling member	499 label Biography information for Lord Campbell-Savours

1259918

registered interest
date	09/12/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what was the incidence of vaccinated people being able to pass on COVID-19 to those who have not been vaccinated in the trial COVID-19 vaccination programmes.
tabling member printed	Lord Campbell-Savours
uin	HL11278
answer	answer is ministerial correction date of answer 17/12/2020 answer text <p>To date the Medicines and Healthcare products Regulatory Agency (MHRA), as well as independent expert advisors on the Commission on Human Medicines and its Expert Working Groups, have completed the assessment of the quality, safety and efficacy data only for the Pfizer/BioNTech vaccine. This vaccine is an mRNA vaccine and data supported a two dose regimen. Efficacy was evaluated in terms of prevention of COVID-19 caused by the SARS-CoV-2 virus, in terms of vulnerability to COVID-19 of the person vaccinated. Clinical trial data showed that, compared to the placebo, efficacy of the Pfizer/BioNTech vaccine from first COVID-19 occurrence from seven days after dose two in participants with or without evidence of prior infection with SARS-CoV-2 was 94.6% - a 95% credible interval of 89.9% to 97.3%).</p><p>There is currently no data available regarding transmission of COVID-19 to others in a person who has been vaccinated using any of the COVID-19 vaccines. There is also currently no data available for any COVID-19 vaccine on the period after vaccination for which a person can remain asymptomatic.</p> answering member printed Lord Bethell grouped question UIN HL11196 HL11197 HL11198 HL11199 HL11279 HL11280 HL11281 question first answered 17/12/2020 13:44:06 answering member 4708 label Biography information for Lord Bethell
tabling member	499 label Biography information for Lord Campbell-Savours

1259919

registered interest
date	09/12/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government for how long a person who has received the two-doses of the COVID-19 vaccine required under the vaccination protocols can remain asymptomatic.
tabling member printed	Lord Campbell-Savours
uin	HL11279
answer	answer is ministerial correction date of answer 17/12/2020 answer text <p>To date the Medicines and Healthcare products Regulatory Agency (MHRA), as well as independent expert advisors on the Commission on Human Medicines and its Expert Working Groups, have completed the assessment of the quality, safety and efficacy data only for the Pfizer/BioNTech vaccine. This vaccine is an mRNA vaccine and data supported a two dose regimen. Efficacy was evaluated in terms of prevention of COVID-19 caused by the SARS-CoV-2 virus, in terms of vulnerability to COVID-19 of the person vaccinated. Clinical trial data showed that, compared to the placebo, efficacy of the Pfizer/BioNTech vaccine from first COVID-19 occurrence from seven days after dose two in participants with or without evidence of prior infection with SARS-CoV-2 was 94.6% - a 95% credible interval of 89.9% to 97.3%).</p><p>There is currently no data available regarding transmission of COVID-19 to others in a person who has been vaccinated using any of the COVID-19 vaccines. There is also currently no data available for any COVID-19 vaccine on the period after vaccination for which a person can remain asymptomatic.</p> answering member printed Lord Bethell grouped question UIN HL11196 HL11197 HL11198 HL11199 HL11278 HL11280 HL11281 question first answered 17/12/2020 13:44:06 answering member 4708 label Biography information for Lord Bethell
tabling member	499 label Biography information for Lord Campbell-Savours

1259920

registered interest
date	09/12/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of whether a person who has been vaccinated against COVID-19 can acquire COVID-19 asymptomatic status without indicators and transmit the virus on to another person who has not been vaccinated.
tabling member printed	Lord Campbell-Savours
uin	HL11280
answer	answer is ministerial correction date of answer 17/12/2020 answer text <p>To date the Medicines and Healthcare products Regulatory Agency (MHRA), as well as independent expert advisors on the Commission on Human Medicines and its Expert Working Groups, have completed the assessment of the quality, safety and efficacy data only for the Pfizer/BioNTech vaccine. This vaccine is an mRNA vaccine and data supported a two dose regimen. Efficacy was evaluated in terms of prevention of COVID-19 caused by the SARS-CoV-2 virus, in terms of vulnerability to COVID-19 of the person vaccinated. Clinical trial data showed that, compared to the placebo, efficacy of the Pfizer/BioNTech vaccine from first COVID-19 occurrence from seven days after dose two in participants with or without evidence of prior infection with SARS-CoV-2 was 94.6% - a 95% credible interval of 89.9% to 97.3%).</p><p>There is currently no data available regarding transmission of COVID-19 to others in a person who has been vaccinated using any of the COVID-19 vaccines. There is also currently no data available for any COVID-19 vaccine on the period after vaccination for which a person can remain asymptomatic.</p> answering member printed Lord Bethell grouped question UIN HL11196 HL11197 HL11198 HL11199 HL11278 HL11279 HL11281 question first answered 17/12/2020 13:44:07 answering member 4708 label Biography information for Lord Bethell
tabling member	499 label Biography information for Lord Campbell-Savours

1259921

registered interest
date	09/12/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of whether (1) an adenovirus vector, and (2) an mRNA, COVID-19 vaccine (a) does not prevent a vaccinated person from contracting COVID-19 but suppresses the symptoms of the disease, or (2) prevents a vaccinated person from contracting COVID-19.
tabling member printed	Lord Campbell-Savours
uin	HL11281
answer	answer is ministerial correction date of answer 17/12/2020 answer text <p>To date the Medicines and Healthcare products Regulatory Agency (MHRA), as well as independent expert advisors on the Commission on Human Medicines and its Expert Working Groups, have completed the assessment of the quality, safety and efficacy data only for the Pfizer/BioNTech vaccine. This vaccine is an mRNA vaccine and data supported a two dose regimen. Efficacy was evaluated in terms of prevention of COVID-19 caused by the SARS-CoV-2 virus, in terms of vulnerability to COVID-19 of the person vaccinated. Clinical trial data showed that, compared to the placebo, efficacy of the Pfizer/BioNTech vaccine from first COVID-19 occurrence from seven days after dose two in participants with or without evidence of prior infection with SARS-CoV-2 was 94.6% - a 95% credible interval of 89.9% to 97.3%).</p><p>There is currently no data available regarding transmission of COVID-19 to others in a person who has been vaccinated using any of the COVID-19 vaccines. There is also currently no data available for any COVID-19 vaccine on the period after vaccination for which a person can remain asymptomatic.</p> answering member printed Lord Bethell grouped question UIN HL11196 HL11197 HL11198 HL11199 HL11278 HL11279 HL11280 question first answered 17/12/2020 13:44:07 answering member 4708 label Biography information for Lord Bethell
tabling member	499 label Biography information for Lord Campbell-Savours

1259442

registered interest
date	08/12/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government to what extent (1) an appropriate person, or (2) the appropriate authorities, can monitor what will happen if a person only receives one of the two doses required of a COVID-19 vaccine under the vaccination protocols; and what the process will be for following up on those people.
tabling member printed	Lord Campbell-Savours
uin	HL11195
answer	answer is ministerial correction date of answer 19/01/2021 answer text <p>General practice providers are responsible under the Enhanced Service Specification: COVID-19 vaccination programme 2020/21 for using existing local systems to undertake local call and recall. They use nationally determined text where available, identifying and inviting all eligible patient cohorts on their registered list to book vaccination appointments. Primary Care Network sites will be responsible for checking that all eligible patients have an appointment and recall invitation or re-contacting the patients where they have not. A booking reminder will be sent before each appointment for dose one and dose two of the vaccine.</p> answering member printed Lord Bethell question first answered 19/01/2021 12:43:32 answering member 4708 label Biography information for Lord Bethell
tabling member	499 label Biography information for Lord Campbell-Savours

1259443

registered interest
date	08/12/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether the COVID-19 planned for use vaccines prevent those vaccinated from transmitting the disease.
tabling member printed	Lord Campbell-Savours
uin	HL11196
answer	answer is ministerial correction date of answer 17/12/2020 answer text <p>To date the Medicines and Healthcare products Regulatory Agency (MHRA), as well as independent expert advisors on the Commission on Human Medicines and its Expert Working Groups, have completed the assessment of the quality, safety and efficacy data only for the Pfizer/BioNTech vaccine. This vaccine is an mRNA vaccine and data supported a two dose regimen. Efficacy was evaluated in terms of prevention of COVID-19 caused by the SARS-CoV-2 virus, in terms of vulnerability to COVID-19 of the person vaccinated. Clinical trial data showed that, compared to the placebo, efficacy of the Pfizer/BioNTech vaccine from first COVID-19 occurrence from seven days after dose two in participants with or without evidence of prior infection with SARS-CoV-2 was 94.6% - a 95% credible interval of 89.9% to 97.3%).</p><p>There is currently no data available regarding transmission of COVID-19 to others in a person who has been vaccinated using any of the COVID-19 vaccines. There is also currently no data available for any COVID-19 vaccine on the period after vaccination for which a person can remain asymptomatic.</p> answering member printed Lord Bethell grouped question UIN HL11197 HL11198 HL11199 HL11278 HL11279 HL11280 HL11281 question first answered 17/12/2020 13:44:06 answering member 4708 label Biography information for Lord Bethell
tabling member	499 label Biography information for Lord Campbell-Savours

1259444

registered interest
date	08/12/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government to what extent a person who receives only one dose of (1) an adenovirus vector, or (2) an mRNA, COVID-19 vaccination is (a) vulnerable to COVID-19 themselves, and (b) able to transmit the disease on to a second person.
tabling member printed	Lord Campbell-Savours
uin	HL11197
answer	answer is ministerial correction date of answer 17/12/2020 answer text <p>To date the Medicines and Healthcare products Regulatory Agency (MHRA), as well as independent expert advisors on the Commission on Human Medicines and its Expert Working Groups, have completed the assessment of the quality, safety and efficacy data only for the Pfizer/BioNTech vaccine. This vaccine is an mRNA vaccine and data supported a two dose regimen. Efficacy was evaluated in terms of prevention of COVID-19 caused by the SARS-CoV-2 virus, in terms of vulnerability to COVID-19 of the person vaccinated. Clinical trial data showed that, compared to the placebo, efficacy of the Pfizer/BioNTech vaccine from first COVID-19 occurrence from seven days after dose two in participants with or without evidence of prior infection with SARS-CoV-2 was 94.6% - a 95% credible interval of 89.9% to 97.3%).</p><p>There is currently no data available regarding transmission of COVID-19 to others in a person who has been vaccinated using any of the COVID-19 vaccines. There is also currently no data available for any COVID-19 vaccine on the period after vaccination for which a person can remain asymptomatic.</p> answering member printed Lord Bethell grouped question UIN HL11196 HL11198 HL11199 HL11278 HL11279 HL11280 HL11281 question first answered 17/12/2020 13:44:06 answering member 4708 label Biography information for Lord Bethell
tabling member	499 label Biography information for Lord Campbell-Savours